secwatch / observer
8-K filed June 23, 2023, 7:59 PM ET ticker JANX CIK 0001817713
leadership confidence high sentiment neutral materiality 0.65

Janux Therapeutics CMO Wayne Godfrey resigns; Chief Strategy Officer Byron Robinson interim lead

Janux Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Wayne Godfrey

Chief Medical Officer
JANX · Janux Therapeutics, Inc.
Effective
2023-07-05
Successor
Byron Robinson
Filed
June 23, 2023, 7:59 PM ET
On June 21, 2023, Wayne Godfrey, M.D. resigned from his position as Chief Medical Officer of Janux Therapeutics, Inc. (the “Company”), effective July 5, 2023.
Appointed (interim)

Byron Robinson

interim head of clinical activities
JANX · Janux Therapeutics, Inc.
Effective
2023-06-23
Filed
June 23, 2023, 7:59 PM ET
On an interim basis and effective immediately, Byron Robinson, Ph.D., the Company’s Chief Strategy Officer, will take over leadership of the Company’s ongoing clinical activities and supervise the Company’s experienced clinical team.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Wayne Godfrey resigned as Chief Medical Officer at Janux Therapeutics, Inc..

Action
resigned
Role
Chief Medical Officer
Exact text from the filing
On June 21, 2023, Wayne Godfrey, M.D. resigned from his position as Chief Medical Officer of Janux Therapeutics, Inc. (the “Company”), effective July 5, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.8

Byron Robinson was appointed as interim head of clinical activities at Janux Therapeutics, Inc..

Action
will take over
Role
interim head of clinical activities
Exact text from the filing
On an interim basis and effective immediately, Byron Robinson, Ph.D., the Company’s Chief Strategy Officer, will take over leadership of the Company’s ongoing clinical activities and supervise the Company’s experienced clinical team.
View on SEC.gov

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0000950170-23-029662
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.